The identification of novel therapeutic targets for the treatment of malignant brain tumors.
about
The human DEK oncogene regulates DNA damage response signaling and repairProduction and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.Dissecting the Potential Interplay of DEK Functions in Inflammation and CancerSolution NMR structure of the N-terminal domain of the human DEK proteinCrystal structures of NAC domains of human nascent polypeptide-associated complex (NAC) and its αNAC subunitExtremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein ScaffoldBreast cancer molecular signatures as determined by SAGE: correlation with lymph node status.Intercellular trafficking of the nuclear oncoprotein DEK.Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry.Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.Control of tumorigenesis and chemoresistance by the DEK oncogeneDual binding mode of the nascent polypeptide-associated complex reveals a novel universal adapter site on the ribosome.High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancerThe human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7Serological analysis of SEREX-defined medullary breast carcinoma-associated antigens.Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cellsDEK over expression as an independent biomarker for poor prognosis in colorectal cancer.DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigenDefining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reactionApoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.The DEK nuclear autoantigen is a secreted chemotactic factorαNAC inhibition of the FADD-JNK axis plays anti-apoptotic role in multiple cancer cellsIdentification of novel cancer therapeutic targets using a designed and pooled shRNA library screenSolution NMR structure of the C-terminal domain of the human protein DEK.Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stressDEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer.Massive human co-expression network and its medical applicationsDEK proto-oncogene expression interferes with the normal epithelial differentiation program.Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivoThe DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.Progress in studies on the DEK protein and its involvement in cellular apoptosis.High expression of DEK predicts poor prognosis of gastric adenocarcinoma.The DEK oncoprotein and its emerging roles in gene regulation.Exploring the roles of basal transcription factor 3 in eukaryotic growth and development.Role of key genetic mutations on increasing migration of brain cancer cells through confinement.Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion.A role for intracellular and extracellular DEK in regulating hematopoiesis.alphaNAC depletion as an initiator of ER stress-induced apoptosis in hypoxia.
P2860
Q24306086-336A628B-008E-496A-8398-A9F80A91DB06Q24814838-7195FFCC-B6A3-4ECC-9287-B53998708DFDQ26783559-271798A7-5581-4218-B541-9F8EF84F7B75Q27649727-6F735414-57F9-4B52-BE61-17307FF6B267Q27666452-D899AE80-C15E-446F-BCCC-4B75E332A19FQ28547051-1FA4F637-63B2-42E1-92DC-2666E82C2A8DQ30410300-F1B21C58-7CC4-4473-98D2-C7B9A8C74586Q30539239-379C4C17-8073-424C-B1AA-05EBB1127E26Q30836364-91345D7C-7FEB-4E5E-9841-C49D5C5FE8E1Q33929637-9DA8BD17-B5A4-450B-9F43-37BBE7EC9F2BQ34096933-3E53B6BB-ECD8-402B-B87D-FE95D6687120Q34111425-EC4A0F2B-661C-4D7F-B07C-50DBE09A5D95Q34121479-7AC23C80-FFDC-403E-877D-C4A3F2E4A713Q34124022-7D00F2F7-28C0-4E3C-962C-34324A4EBBCBQ34308955-54B4B785-51A9-4DD2-BD2F-073074A68E92Q34353406-4CC6353D-91D6-40AF-B2BF-8A76BECA4E52Q34884622-9FE00295-935C-4A6E-AE9E-4B2949B8AEE1Q34991689-3A945FE6-AB27-43A9-BC52-050CAE7F8029Q35051109-F2972F38-250E-40E8-9050-A3BF6D7E1842Q35083274-CFC68E69-9375-4F1E-8945-156975B70BE6Q35131718-AA38FDDA-BC32-49CD-BA7E-AADCC3DA9EEDQ35221391-3069F7A3-8C8C-45D4-987C-A444E947F12AQ36179529-9A8536A2-4DE5-4241-9F9B-8303D1D74D46Q36287067-344D356A-A2A9-48BF-BE67-992B4236EA9EQ36519194-19D15310-8CCB-47F2-99C9-5C8A254A5A18Q36524257-5E23C8AF-CBED-43CD-9345-59ADB0F7D030Q36710870-C099F31D-DD82-48C5-9F75-58FFE18C70FEQ36999751-0E2BF7C3-7D6D-4BD0-8FD8-C47EF688852AQ37013849-88E603C3-F3F5-4F7D-9C49-52ABD5D68A6BQ37073767-D2C07C07-3F39-4F3B-8EE6-6889F8C56F44Q37116215-3EF8126D-C459-4AFA-AC7E-FA5641F8E08DQ37269117-57CE5068-7D6D-49AC-A380-25709954EA4FQ37566333-06E43DD2-912D-49DA-B17B-40B5D3F26E36Q37714805-576402A7-B7C6-4886-A0CD-2CD70BC66381Q38375804-42324649-F569-4B2B-95C2-47725FEA0170Q38597330-751C0E72-A98F-4EE4-96D3-034473F7D357Q38723005-68999707-148C-4FA5-A86F-3BDEFC1D4A71Q39064803-2D96717B-9374-408B-B55E-339B83FB9C96Q39184178-CC6C8FCC-72E3-4D79-8613-8C644B9DCFE7Q39824387-C85BD4B3-685E-4DCD-900B-C08EE67163D7
P2860
The identification of novel therapeutic targets for the treatment of malignant brain tumors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The identification of novel th ...... ent of malignant brain tumors.
@ast
The identification of novel th ...... ent of malignant brain tumors.
@en
type
label
The identification of novel th ...... ent of malignant brain tumors.
@ast
The identification of novel th ...... ent of malignant brain tumors.
@en
prefLabel
The identification of novel th ...... ent of malignant brain tumors.
@ast
The identification of novel th ...... ent of malignant brain tumors.
@en
P2093
P1433
P1476
The identification of novel th ...... ent of malignant brain tumors.
@en
P2093
D S Kersey
E Mkrdichian
H Yamamoto
J R Moskal
M G McLone
P304
P356
10.1016/S0304-3835(00)00462-6
P407
P577
2000-08-01T00:00:00Z